1. Home
  2. NEPH vs STTK Comparison

NEPH vs STTK Comparison

Compare NEPH & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEPH
  • STTK
  • Stock Information
  • Founded
  • NEPH 1997
  • STTK 2016
  • Country
  • NEPH United States
  • STTK United States
  • Employees
  • NEPH N/A
  • STTK N/A
  • Industry
  • NEPH Medical/Dental Instruments
  • STTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEPH Health Care
  • STTK Health Care
  • Exchange
  • NEPH Nasdaq
  • STTK Nasdaq
  • Market Cap
  • NEPH 36.1M
  • STTK 37.6M
  • IPO Year
  • NEPH 2004
  • STTK 2020
  • Fundamental
  • Price
  • NEPH $4.03
  • STTK $0.83
  • Analyst Decision
  • NEPH Buy
  • STTK Hold
  • Analyst Count
  • NEPH 1
  • STTK 4
  • Target Price
  • NEPH $5.00
  • STTK $3.00
  • AVG Volume (30 Days)
  • NEPH 67.9K
  • STTK 401.8K
  • Earning Date
  • NEPH 08-07-2025
  • STTK 07-31-2025
  • Dividend Yield
  • NEPH N/A
  • STTK N/A
  • EPS Growth
  • NEPH N/A
  • STTK N/A
  • EPS
  • NEPH 0.08
  • STTK N/A
  • Revenue
  • NEPH $15,517,000.00
  • STTK $4,606,000.00
  • Revenue This Year
  • NEPH $17.06
  • STTK N/A
  • Revenue Next Year
  • NEPH $12.20
  • STTK N/A
  • P/E Ratio
  • NEPH $53.08
  • STTK N/A
  • Revenue Growth
  • NEPH 10.34
  • STTK 69.65
  • 52 Week Low
  • NEPH $1.36
  • STTK $0.69
  • 52 Week High
  • NEPH $5.00
  • STTK $4.99
  • Technical
  • Relative Strength Index (RSI)
  • NEPH 56.63
  • STTK 39.19
  • Support Level
  • NEPH $3.83
  • STTK $0.77
  • Resistance Level
  • NEPH $4.39
  • STTK $0.91
  • Average True Range (ATR)
  • NEPH 0.47
  • STTK 0.08
  • MACD
  • NEPH -0.07
  • STTK -0.02
  • Stochastic Oscillator
  • NEPH 43.27
  • STTK 16.23

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: